Search results
Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing...
WROC Rochester· 2 days agoNovartis today presented results from the 6-month, double-blind period of the Phase III APPEAR-C3G...
Arizona House advances immigration resolution amid racial profiling claims
Courthouse News Service· 5 days agoArizona's Senate floor session ended in chaos Wednesday as members of the gallery shouted out in...
Michael Sugrue, 66, Dies; His Talks on Philosophy Were a YouTube Hit
New York Times· 2 days agoAfter an academic career spent in near obscurity, he became an internet phenomenon during the...
Stanley Cup playoffs picks: Who wins Rangers-Panthers, Stars-Oilers?
ESPN· 5 days agoThe postseason field is down to four. Who makes the Stanley Cup Final? Our ESPN hockey experts make...
Senate Republicans approve sending ‘secure border’ act to the November ballot
Arizona Mirror via Yahoo News· 4 days agoRepublicans in the Arizona Senate approved a proposal on Wednesday that seeks to give police...
Arizona Senate votes to send border policing measure to ballot
Arizona Daily Star· 5 days agoState senators decided late Wednesday to ask voters to make it a state crime to enter Arizona from...
The top five places to visit in County Monaghan
Irish Central· 4 days agoThis border county was also the birthplace of actor Ardal O’Hanlon, most famous for his legendary character Father Dougal in the hit Irish TV show...
Instant recap: Notre Dame lacrosse beats Denver in NCAA men's semifinal, will defend title
South Bend Tribune· 2 days agoNotre Dame lacrosse is looking to become the 10th team to win back-to-back NCAA men's lacrosse...
Memorial Day Weekend Watch: Each Team's Superpower and Kryptonite
Inside Lacrosse· 3 days agoThis weekend, the men’s lacrosse community will gather at Lincoln Financial Field to witness the...
Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing...
KSAN - KLST San Angelo· 2 days agoNovartis today presented results from the 6-month, double-blind period of the Phase III APPEAR-C3G study of Fabhalta® (iptacopan) at the late-breaking clinical trials session of the European ...